Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec 3:5:395-402.
doi: 10.2147/CIA.S14570.

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Sumanta Kumar Pal  1 , Przemyslaw Twardowski, Oliver Sartor
Affiliations
Review

Critical appraisal of cabazitaxel in the management of advanced prostate cancer

Sumanta Kumar Pal et al. Clin Interv Aging. .

Abstract

Docetaxel remains a cornerstone of therapy for the patient with metastatic castration-resistant prostate cancer (CRPC). However, the landscape of CRPC therapy is changing rapidly - recently, data from the phase III TROPIC study revealed a survival advantage with the novel taxane cabazitaxel/prednisone (compared with mitoxantrone/prednisone) in a cohort of 755 men with docetaxel-refractory metastatic CRPC. Interestingly, cabazitaxel bears substantial structural similiarity to docetaxel but appears to be mechanistically distinct. In preclinical studies, the agent has antitumor activity in a variety of docetaxel-refractory in vitro and in vivo models. Subsequent to phase I testing in advanced solid tumors (where neutropenia was identified as a dose-limiting toxicity), the agent was assessed in a phase II trial in advanced, taxane-refractory breast cancer and in the aforementioned phase III TROPIC study. This review describes in detail the preclinical and clinical development of cabazitaxel.

Keywords: Jevtana; breast cancer; cabazitaxel; castration resistant prostate cancer; taxane.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Existing and evolving paradigms in the treatment of metastatic prostate cancer. Abbreviation: LHRH, luteinizing hormone releasing hormone.
Figure 2
Figure 2
The chemical structure of cabazitaxel (C45H57 NO14…C3H6O, MW = 894.01). Highlighted in red are methoxy side chains that substitute hydroxyl groups found in docetaxel.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. Wiley Subscription Services, Inc., A Wiley Company; 2010.
    1. Wayland H, Kelvin AM, Michael G, Ashesh BJ, Peter JR, Viraj AM. Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease. J Urol. 2010;184(2):512–518. - PubMed
    1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–297. - PubMed
    1. Huggins C, Stevens RE, Jr, Hodges CV. Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209–223.
    1. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007;12:4957–4971. - PubMed

Publication types

MeSH terms